Edward Kerwin1, Gary T Ferguson2, Shahin Sanjar3, Thomas Goodin3, Anthony Yadao4, Robert Fogel4, Samopriyo Maitra5, Biswajit Sen5, Tim Ayers4, Donald Banerji6. 1. Clinical Research Institute, Medford, OR, USA. 2. Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA. 3. Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA, USA. 4. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. 5. Novartis Healthcare Pvt. Ltd., Hyderabad, India. 6. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. donald.banerji@novartis.com.
Abstract
PURPOSE: To compare the efficacy and safety of two long-acting dual bronchodilator combinations: indacaterol/glycopyrrolate (IND/GLY) versus umeclidinium/vilanterol (UMEC/VI). METHODS: Studies A2349 and A2350 were replicate, randomized, double-blind, double-dummy, active-controlled, cross-over studies in patients with moderate-to-severe COPD. Patients were randomized to sequential 12-week treatments of twice-daily IND/GLY 27.5/15.6 μg and once-daily UMEC/VI 62.5/25 μg, each separated by a 3-week washout. The primary objective was to demonstrate non-inferiority of IND/GLY compared with UMEC/VI in terms of the 24-h forced expiratory volume in 1 s profile at week 12 (FEV1 AUC0-24). Rescue medication use, symptom control, and safety were assessed throughout. RESULTS: Both treatments delivered substantial bronchodilation over 12 weeks, with improvements in FEV1 AUC0-24h at week 12 of 232 and 185 mL for IND/GLY, and 244 and 203 mL with UMEC/VI in Studies A2349 and A2350, respectively. The primary efficacy objective of non-inferiority of IND/GLY relative to UMEC/VI was not met as the lower bound of the confidence interval for the LS treatment comparison was below the pre-specified non-inferiority margin of -20 mL in both studies: -26.9 and -34.2 mL, respectively (LS mean between-treatment differences: -11.5 and -18.2 mL). Both drugs were well tolerated, with AE profiles consistent with their respective prescribing information. CONCLUSIONS: IND/GLY and UMEC/VI provided clinically meaningful and comparable bronchodilation. Non-inferiority of IND/GLY to UMEC/VI could not be declared although between-treatment differences were not clinically relevant. The data support the use of IND/GLY as an efficacious and well tolerated treatment option in patients with COPD. (ClinicalTrials.gov NCT02487446 and NCT02487498).
RCT Entities:
PURPOSE: To compare the efficacy and safety of two long-acting dual bronchodilator combinations: indacaterol/glycopyrrolate (IND/GLY) versus umeclidinium/vilanterol (UMEC/VI). METHODS: Studies A2349 and A2350 were replicate, randomized, double-blind, double-dummy, active-controlled, cross-over studies in patients with moderate-to-severe COPD. Patients were randomized to sequential 12-week treatments of twice-daily IND/GLY 27.5/15.6 μg and once-daily UMEC/VI 62.5/25 μg, each separated by a 3-week washout. The primary objective was to demonstrate non-inferiority of IND/GLY compared with UMEC/VI in terms of the 24-h forced expiratory volume in 1 s profile at week 12 (FEV1 AUC0-24). Rescue medication use, symptom control, and safety were assessed throughout. RESULTS: Both treatments delivered substantial bronchodilation over 12 weeks, with improvements in FEV1 AUC0-24h at week 12 of 232 and 185 mL for IND/GLY, and 244 and 203 mL with UMEC/VI in Studies A2349 and A2350, respectively. The primary efficacy objective of non-inferiority of IND/GLY relative to UMEC/VI was not met as the lower bound of the confidence interval for the LS treatment comparison was below the pre-specified non-inferiority margin of -20 mL in both studies: -26.9 and -34.2 mL, respectively (LS mean between-treatment differences: -11.5 and -18.2 mL). Both drugs were well tolerated, with AE profiles consistent with their respective prescribing information. CONCLUSIONS: IND/GLY and UMEC/VI provided clinically meaningful and comparable bronchodilation. Non-inferiority of IND/GLY to UMEC/VI could not be declared although between-treatment differences were not clinically relevant. The data support the use of IND/GLY as an efficacious and well tolerated treatment option in patients with COPD. (ClinicalTrials.gov NCT02487446 and NCT02487498).
Authors: Robert A Wise; Antonio Anzueto; Daniel Cotton; Ronald Dahl; Theresa Devins; Bernd Disse; Daniel Dusser; Elizabeth Joseph; Sabine Kattenbeck; Michael Koenen-Bergmann; Gordon Pledger; Peter Calverley Journal: N Engl J Med Date: 2013-08-30 Impact factor: 91.245
Authors: Donald A Mahler; Edward Kerwin; Tim Ayers; Angel FowlerTaylor; Samopriyo Maitra; Chau Thach; Mark Lloyd; Francesco Patalano; Donald Banerji Journal: Am J Respir Crit Care Med Date: 2015-11-01 Impact factor: 21.405
Authors: Andrea Rossi; Thys van der Molen; Ricardo del Olmo; Alberto Papi; Luis Wehbe; Matthew Quinn; Chengxing Lu; David Young; Ray Cameron; Enrica Bucchioni; Pablo Altman Journal: Eur Respir J Date: 2014-10-30 Impact factor: 16.671
Authors: Donald P Tashkin; Stephen I Rennard; Paula Martin; Sulabha Ramachandran; Ubaldo J Martin; Philip E Silkoff; Mitchell Goldman Journal: Drugs Date: 2008 Impact factor: 9.546
Authors: Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski Journal: Am J Respir Crit Care Med Date: 2007-05-16 Impact factor: 21.405
Authors: Claus F Vogelmeier; Mina Gaga; Maryam Aalamian-Mattheis; Timm Greulich; Jose M Marin; Walter Castellani; Vincent Ninane; Stephen Lane; Xavier Nunez; Francesco Patalano; Andreas Clemens; Konstantinos Kostikas Journal: Respir Res Date: 2017-07-18
Authors: Brian O'Doherty; Jane Dorman; Karen McGrath; Kevin Kelly; David Molony; Seán Lacey; Sarah Whelan; Simon Schmid; Shane Sullivan Journal: Ir J Med Sci Date: 2019-03-28 Impact factor: 1.568
Authors: John R Hurst; Kevin Gruffydd-Jones; Mousumi Biswas; Deniz Guranlioglu; Martin Jenkins; Neda Stjepanovic; Arushi Bamrara Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-07-01
Authors: Timothy E Albertson; Willis S Bowman; Richart W Harper; Regina M Godbout; Susan Murin Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-06-06